US-based clinical development firm AltheRx Pharmaceuticals has received a notice of allowance for its patent application from the US Patent and Trademark Office (USPTO) for the use of solabegron in combination with antimuscarinics at both ...
Astellas Pharma Canada has introduced Myrbetriq (mirabegron, extended-release tablets) as overactive bladder (OAB) therapy in Canada. Myrbetriq is indicated to treat OAB with symptoms of urge urinary incontinence, urgency and urinary ...
The USFDA has approved Allergan's Botox (onabotulinumtoxinA) as overactive bladder (OAB) therapy for adults who do not respond to or who cannot tolerate an anticholinergic medication. The approval was based on safety and efficacy data ...
Tags: FDA, Allergan overactive bladder, anticholinergic treatments